TNFSF10 and neoplasm: Both pre-clinical and clinical studies with recombinant human soluble TRAIL (rhsTRAIL) or TRAIL-receptor agonist (anti-TRAIL-R1 and anti-TRAIL-R2) have shown remarkable anticancer effects in a wide range of tumor types [11,12,13,14].